Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

被引：0
|
作者：
Kwiatek, Michal [1 ]
Grosicki, Sebastian [2 ]
Lopez Jimenez, Javier [3 ]
Pinzon Marino, Sergio Felipe [4 ]
Snauwaert, Sylvia [5 ]
Kingsley, Edwin [6 ]
Zacchetti, Giovanna [7 ]
Wang, Ying [8 ]
Wang, Luqiang [8 ]
Depaus, Julien [9 ]
机构：
[1] Ctr Med Pratia Poznan, Skorzewo, Poland
[2] Med Univ Silesia, Katowice, Poland
[3] Hosp Univ Ramon & Cajal, Madrid, Spain
[4] Hosp del Mar, Dept Clin Hematol, Barcelona, Spain
[5] Algemeen Ziekenhuis Sint Jan Brugge Oostende Camp, Brugge, Belgium
[6] Comprehens Canc Centers Nevada, Las Vegas, NV USA
[7] ADC Therapeut SA, Epalinges, Switzerland
[8] ADC Therapeut Amer Inc, Murray Hill, NJ USA
[9] Univ Catholique Louvain (UCL), Ctr Hosp Univ CHU, Namur Site Godinne, Yvoir, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
aggressive B-cell lymphoma (ABCL); B cell; non-Hodgkin lymphoma; loncastuximab tesirine; rituximab; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-515
引用
收藏
页码：S439 / S440
页数：2
相关论文
共 30 条
  • [1] Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
    Kingsley, Edwin
    Grosicki, Sebastian
    Kwiatek, Michal
    Salar, Antonio
    Snauwaert, Sylvia
    Wang, Ying
    Adamis, Helena
    Wang, Luqiang
    Depaus, Julien
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S372 - S372
  • [2] Phase 3 randomized study of loncastuximab tesirine in combination with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL (LOTIS-5).
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    Kingsley, Ed
    Depaus, Julien
    Snauwaert, Sylvia
    Kwiatek, Michal
    Lopez-Jimenez, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL
    Kwiatek, Michal T.
    Carlo-Stella, Carmelo
    Urban, Andrzej
    Niewiarowski, Andrew
    Wang, Luqiang
    Laughlin, Mary
    Hamadani, Mehdi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S473 - S474
  • [4] LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.
    Kwiatek, Michal
    Carlo-Stella, Carmelo
    Urban, Andrzej
    Niewiarowski, Andrew
    Wang, Luqiang
    Hamadani, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)
    Westin, Jason
    Burke, John M.
    Chapman, Andrew E.
    Kilavuz, Turk
    Xu, Cindy
    Schmuely, Yochi
    Stanford, Brad Lane
    Beedle, Emily
    Radford, John
    BLOOD, 2022, 140 : 6638 - 6639
  • [7] ONSET, DURATION, AND MANAGEMENT OF EDEMA AND EFFUSION IN PATIENTS TREATED WITH LONCASTUXIMAB TESIRINE FOR R/R DLBCL: UPDATED RESULTS FROM THE LOTIS-2 CLINICAL TRIAL
    Grandas, Claudia
    Hendrickson, Lindsey
    Alderuccio, Juan Pablo
    Hess, Brian
    Ungar, David
    Solh, Melhem
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : E56 - E56
  • [8] A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9)
    Westin, Jason
    Burke, John M.
    Chapman, Andrew E.
    Kilavuz, Turk
    Xu, Cindy
    Shmuely, Yochi
    Radford, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S368 - S368
  • [9] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Izquierdo, Antonia Rodriguez
    Martin, Eva Maria Donato
    Garcia-Sancho, Alejandro Martin
    Sandoval-Sus, Jose David
    Tilly, Herve
    Vandenberghe, Elizabeth
    Hirata, Jamie
    Choudhry, Priya
    Chang, Yi Meng
    Musick, Lisa
    McMillan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Pola-R-ICE: Results of the safety run-in phase of a phase III study comparing polatuzumab vedotin in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) with R-ICE alone in patients with refractory or relapsed diffuse large B-cell lymphoma
    Laube, A.
    Fuhrmann, S.
    Van Heteren, P.
    Ziepert, M.
    Altmann, B.
    Davies, A.
    Greil, R.
    Garcia-Sancho, A. M.
    Gonzalez De Villambrosia Pellon, S.
    Schnetzke, U.
    De la Cruz Vicente, F.
    Haenel, M.
    Hess, G.
    Koehler, C.
    Masius, H.
    Glass, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 83 - 84
123